Parkinson's Disease Center and Movement Disorders Clinic
|
|
- Dylan Reeves
- 6 years ago
- Views:
Transcription
1 Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas phone Botulinum Toxin Botulinum toxin (BTX) has been used at Baylor College of Medicine Movement Disorders Clinic in the treatment of dystonia and related disorders since Its safety and efficacy has been established, partly as a result of the pioneering work at the Movement Disorder Clinic. The first double-blind, placebo controlled trial of BTX in cranial-cervical dystonia was conducted at Baylor and the findings were used to obtain the initial approval for BTX by the Food and Drug Administration. Dystonia is a neurological condition manifested by involuntary contractions (spasms) of muscles producing twisting, squeezing or pulling movements and abnormal postures. Examples of dystonia include blepharospasm (spasms of eyelids causing involuntary eye closure), cervical dystonia or torticollis (spasms of neck muscles causing twisting and other movements of the neck, abnormal head posture, and neck pain), laryngeal dystonia or spasmodic dysphonia (spasms of vocal cords causing a strained or breathy voice), oromandibular (mouth and jaw spasms) dystonia, and task-specific dystonias (writer's cramps). In addition to dystonias, BTX has been used also to relieve other focal spasms, such as hemifacial spasms, tremors, tics, spasticity, and other movement disorders. At Baylor Movement Disorders Clinic, BTX has been also used to treat muscle contraction (tension) and migraine headaches, excessive drooling (sialorrhea), excessive sweating (hyperhidrosis), and other conditions for which BTX has been found to be effective. Studies involving thousands of patients have demonstrated the usefulness and safety of BTX treatments in these conditions. BTX is a protein that acts by binding to certain nerve endings thus preventing the release of the neurotransmitter acetylcholine. An injection of BTX into the muscle blocks transmission of impulses from the nerve to the muscle causing local and temporary weakness of the target muscle. This process, called 1
2 "chemodenervation," provides effective relief of dystonias and other disorders manifested by abnormal and unwanted muscular contractions or abnormal secretions. The onset of improvement is often noted within a few days after injection and the benefits usually wear off after 3 to 6 months at which time a repeat injection is needed. Because BTX acts only locally without spreading into the circulation, it does not usually cause any systemic reactions. Most patients obtain safe and substantial relief, but a few experience side effects after the treatment. Except for occasional temporary feeling of generalized malaise and weakness, nearly all other side effects are confined to the injected body part. Injections into the eyelids, for example, may result in transient local swelling, droopy eyelids, blurring of vision, and tearing. Injections into the neck muscles may cause temporary neck weakness or pain and difficulties with swallowing. Swallowing problems as well as chewing, speech and voice difficulties may also result from injections into the jaw and vocal cord muscles. Injections into the arm or hand muscles may cause temporary weakness of fingers and hands. These side effects are usually mild, occur infrequently, and most resolve in a few weeks without any specific treatment. If swallowing problems occur, it is advisable to change to a soft or liquid diet. Any troublesome side effects should be reported to the treating or primary care physician. BTX treatments do not represent a cure, but they usually provide satisfactory relief of symptoms that can be maintained by repeating treatments when the effects of previous BTX injections begin to wear off. Rarely, some patients become unresponsive to the treatment because they develop blocking antibodies. Such immunoresistance is quite uncommon and occurs only after repeated treatments, usually with relatively high doses or when injected more frequently than every 2-3 months. There are several ways that the presence of immunoresistance can be detected. The simplest and least expensive way is to inject small amounts of BTX into the inner portion of right eyebrow. If the eyebrow is weakened by the injection and one week later the patient is unable to contract the muscle on that side while frowning, this indicates that the patient does not have blocking antibodies no immunoresistance. Besides this unilateral brow injection (UBI), BTX antibodies can 3
3 be also detected by a mouse bioassay. This test involves sending a frozen blood serum to Northview Pacific Laboratories, th St., Berkeley, CA 94710, (510) When the blood sample is forwarded to the Northview Pacific Laboratories by physicians other than those at Baylor, it is important that you are identified as a patient at Baylor College of Medicine and that the results are forwarded to us. Patients who have become immunoresistant as a result of BTX antibodies no longer respond to subsequent injections with the same type of BTX-A, but may respond to other types of BTX. In December 1989, after extensive laboratory and clinical testing of BTX-A (Botox, Allergan Pharmaceuticals, California) the Food and Drug Administration approved this biologic as a therapeutic agent in patients with strabismus, blepharospasm and other facial nerve disorders, including hemifacial spasm. In December 2000, the FDA approved Botox and BTX-B (MYOBLOC, Solstice Neurosciences, Inc., California) as a treatment for cervical dystonia. In 2002, FDA also approved Botox for treatment of frown lines between the brows and in 2004 BTX was approved for severe underarm sweating (hyperhidrosis). In 2010, Botox received approval for spasticity and headaches. Other indications are still pending. Two variants of botulinum toxin A (Dysport and Xeomin ) were recently introduced to the market in 2009 and 2010 respectively. Both are indicated to treat cervical dystonia in Botox naïve and previously treated patients. Changes in the chemical structure of the botulinum toxin A are being evaluated to promote a shorter onset of effect, but generated shorter duration of benefit. The procedure requires specialized skills and, therefore, only some centers are performing this treatment. The actual cost of the medication and procedure depends on the total dose and sites required to treat the specific condition and will be determined at the time of the visit. To cover the cost of the medication and our overhead, we require that all charges for the medication and for the procedure must be paid or a documentation of pre-approval is presented before the treatment visit. Diagnostic Codes for Filing Insurance Claims 4
4 We are genuinely concerned about the cost of the BTX treatments and we are trying to keep the cost as low as possible. Due to the FDA approval (at least for some indications), many insurance carriers and Medicare provide reimbursement for the cost of the BTX and the chemodenervation procedure. The following codes should be used for filing claims: Diagnostic Codes for Filling Insurance Claims Diagnosis Diagnostic Code Procedure/Treatment (CPT) Blepharospasm Dystonia Torticollis Hemifacial spasm Tremor Spasmodic dysphonia OnabotulinumtoxinA (BOTOX ) - J0585 RimabotulinumtoxinB (MYOBLOC ) - J3490 AbobotulinumtoxinA (DYSPORT ) - J0568 IncobotulinumtoxinB (XEOMIN ) - Q2040 Selected References Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA.2011;305: Aguirregomozcorta M, Pagonabarraga J, Diaz-Manera J, et al. Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck. Parkinsonism Relat Disord : Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 2015;125(8): Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxina (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci
5 Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W; Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65: Comella CL, Jankovic J, Truong DD, et al. Efficacy and safety of incobotulinumtoxina (NT 201, XEOMIN, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1 2): Charles D, Brashear A, Hauser RA, et al. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012;35(5): Jankovic J. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol. 2009;16 Suppl 2:14-8. Jankovic J, Hunter C, Dolimbek BZ, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67: Jankovic J. Botulinum toxin: state of the art. Mov Disord. 2017;32(8): Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon [Epub ahead of print] Jinnah HA, Comella CL, Perimutter J, Lungu C, Hallett M, Dystonia Coalition Investigators. Longitudinal studies of botulinum toxin in cervical dystonia: why do patients discontinue therapy? Toxicon [Epub ahead of print] Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, de Haan RJ, Speelman JD. Botulinum toxin for writer's cramp: a randomized, placebo-controlled trial and 1- year follow-up. J Neurol Neurosurg Psychiatry. 2007;78: Lolekha P, Choolam A, Kuklantrakom K. A comparative crossover study of the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques. Neurol Sci [Epub ahead of print] Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety and immunogenicity. Mov Disord.2005;20: Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum toxin in Parkinson disease tremor: a randomized, double-blind, placebo-controlled study with a customized injection approach. Mayo Clin Proc. 2017;92(9):
6 Ni J, Wang X, Cao N, Si J, Gu B. Is repeat botulinum toxin A injection valuable for neurogenic detrusor overactivity a systematic review and meta-analysis. Neurourol Urodyn [Epub ahead of print] Ramirez-Castaneda J, Jankovic J, Comella C, et al. Diffusion, spread, and migration of botulinum toxin. Mov Disord Nov;28 (13): Samotus O, Lee J, Jog M. Long-term tremor therapy for Parkinson and essential tremor with sensor-guided botulinum toxin type A injections. PLoS One. 2017;12(6):1-19. Santamato A, Panza F, Intiso D, Baricich, Picelli A, Smania N, Fortunato F, Seripa D, Fiore P, Ranieri M. Long-term safety of repeated high doses of incobotulinumtoxina injections for the treatment of upper and lower limb spasticity after stroke. J Neurol Sci. 2017;378: Scheps D, de la Paz ML, Jurk M, Hofmann F, Frevert J. Design of modified botulinum neurotoxin A1 variants with a shorter persistence of paralysis and duration of action. Toxicon [Epub ahead of print] Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A; BoNT/TZD Study Team. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebocontrolled study. J Neurol Neurosurg Psychiatry. 2009;80: Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2016;86(19): International Neurotoxin Association 7
THE CLINICAL USE OF BOTULINUM TOXIN IN THE TREATMENT OF MOVEMENT DISORDERS, SPASTICITY, AND SOFT TISSUE PAIN
THE CLINICAL USE OF BOTULINUM TOXIN IN THE TREATMENT OF MOVEMENT DISORDERS, SPASTICITY, AND SOFT TISSUE PAIN Spasmodic torticollis (cervical dystonia), blepharospasm, and writer s cramp are specific types
More informationParkinson's Disease Center and Movement Disorders Clinic
Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Blepharospasm Diagnosis Involuntary facial movements
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other ONABOTULINUMTOXINA BOTOX 04867 BRAND BOTOX COSMETIC ABOBOTULINUMTOXINA DYSPORT 36477 RIMABOTULINUMTOXINB MYOBLOC 21869 INCOBOTULINUMTOXINA XEOMIN 36687 Please use
More informationNeuromuscular Blocking Agents
Neuromuscular Blocking Agents DRUG POLICY This Prior Authorization request will be reviewed for medical necessity only. Benefits are subject to the terms and conditions of the patient s contract. Please
More informationBOTOX. Description. Section: Prescription Drugs Effective Date: January 1, 2013 Subsection: CNS Original Policy Date: December 7, 2011
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.12.01 Subject: Botox Page: 1 of 6 Last Review Status/Date: December 6, 2012 BOTOX Description Botox (onabotulinum
More informationBotox. Botox (onabotulinum toxin A) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.01 Subject: Botox Page: 1 of 8 Last Review Date: September 15, 2017 Botox Description Botox (onabotulinum
More informationBOTOX (onabotulinumtoxina) for Therapeutic Use
BOTOX (onabotulinumtoxina) for Therapeutic Use BOTOX (onabotulinumtoxina) & BOTOX Cosmetic (onabotulinumtoxina) Important Information IMPORTANT SAFETY INFORMATION BOTOX and BOTOX Cosmetic may cause serious
More informationMEDICATION GUIDE BOTOX BOTOX Cosmetic (Boe-tox) (onabotulinumtoxina) for Injection
17.2 Ability to Operate Machinery or Vehicles Advise patients that if loss of strength, muscle weakness, blurred vision, or drooping eyelids occur, they should avoid driving a car or engaging in other
More informationBotulinum toxins: abobotulinumtoxina (Dysport ), incobotulinumtoxina (Xeomin ), onabotulinumtoxina (Botox ), & rimabotulinumtoxinb (Myobloc )
Botulinum toxins: abobotulinumtoxina (Dysport ), incobotulinumtoxina (Xeomin ), onabotulinumtoxina (Botox ), & rimabotulinumtoxinb (Myobloc ) These services may or may not be covered by your HealthPartners
More informationHemifacial spasm. Parkinson's Disease Center and Movement Disorders Clinic
Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Hemifacial spasm Diagnosis Hemifacial spasm
More informationBotox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb)
Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date:
More informationParkinson's Disease Center and Movement Disorders Clinic
Parkinson's Disease Center and Movement Disorders Clinic 7200 Cambridge Street, 9th Floor, Suite 9A Houston, Texas 77030 713-798-2273 phone www.jankovic.org Dystonia Diagnosis Dystonia is a neurologic
More informationClare Gaduzo BSc RMN Registered Aesthetics Practitioner (qualified with Medics Direct)
Clare Gaduzo BSc RMN Registered Aesthetics Practitioner (qualified with Medics Direct) 07935567067 cjg.aesthetics@yahoo.co.uk www.cjgaesthetics.co.uk http://www.facebook.com/cjgaesthetics @CJGAesthetics
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH MICHIGA Botulinum Toxins (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationMYOBLOC and Cervical Dystonia A Patient s Guide
MYOBLOC and Cervical Dystonia A Patient s Guide MYOBLOC (rimabotulinumtoxinb) Injection is indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 4/2/19. IncobotulinumtoxinA
IncobotulinumtoxinA NDC CODE(S) 00259-1605-XX Xeomin 50 UNIT SOLR (MERZ PHARMACEUTICAL) 00259-1610-XX Xeomin 100 UNIT SOLR (MERZ PHARMACEUTICAL) 00259-1620-XX Xeomin 200 UNIT SOLR (MERZ PHARMACEUTICAL)
More informationMedication Prior Authorization Form
(OnabotulinumtoxinA) Dysport (abobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Xeomin (incobotulinumtoxina) Policy Number: 1042 Policy History Approve Date: 12/11/2015 Revise Dates: 7/7/2016 Next Review:
More informationBotox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb)
Botox (onabotulinumtoxina) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.
Local Coverage Determination (LCD): Drugs and Biologicals: Botulinum Toxins (L34253) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information
More informationAntibody-Induced Failure of Botulinum Toxin A Therapy in Cosmetic Indications
Antibody-Induced Failure of Botulinum Toxin A Therapy in Cosmetic Indications DIRK DRESSLER, MD, PHD, KAI WOHLFAHRT, MD, PHD, y ELLEN MEYER-ROGGE, MD, z LUITGARD WIEST, MD, y AND HANS BIGALKE, MD, PHD
More informationBotox. Botox (onabotulinum toxin A) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.01 Subject: Botox Page: 1 of 10 Last Review Date: November 30, 2018 Botox Description Botox (onabotulinum
More informationTable of Contents. 1.0 Description of the Procedure, Product, or Service Safety and Provider Compliance... 1
Table of Contents 1.0 Description of the Procedure, Product, or Service... 1 1.1 Safety and Provider Compliance... 1 2.0 Eligibility Requirements... 1 2.1 Provisions... 1 2.1.1 General... 1 2.1.2 Specific...
More informationBotox , The Patient Education Institute, Inc. rxf60101 Last reviewed: 01/11/2018 1
Botox Introduction Botox is a well known brand name for a medicinal form of a toxin, or poison. When injected in small doses into specific muscles, Botox doesn't poison you. Instead, it acts as a muscle
More informationHarald Hefter, 1 Christian Hartmann, 1 Ulrike Kahlen, 1 Marek Moll, 1 Hans Bigalke 2
Open Access Research Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins a single
More informationCircle Yes or No Y N. [If yes, no further questions.]
02/18/2016 Prior Authorization AETA BETTER HEALTH PE MEDICAID & AETA BETTER HEALTH KIDS Botulinum Toxins (PA88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationInformed Consent Form
Informed Consent Form Botox Cosmetic (onabotulinumtoxin A) Dysport (abobotulinumtoxin A) Xeomin (incobotulinumtoxin A) INSTRUCTIONS This is an informed-consent document that has been prepared to help inform
More informationMERZ NEUROSCIENCES to PRESENT XEOMIN (incobotulinumtoxina) DATA AT THE 21 ST INTERNATIONAL CONGRESS OF PARKINSON S DISEASE AND MOVEMENT DISORDERS
MERZ NEUROSCIENCES to PRESENT XEOMIN (incobotulinumtoxina) DATA AT THE 21 ST INTERNATIONAL CONGRESS OF PARKINSON S DISEASE AND MOVEMENT DISORDERS MERZ TO PRESENT FIVE POSTERS INCLUDING LATE BREAKER RALEIGH,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: botulinum_toxin_injection 8/1985 10/2017 10/2018 10/2017 Description of Procedure or Service Description
More informationIN ADUL T SUBJECTS WITH BLEPHAROSPASM ACROSS DOSING INTE R VAL S
Poster number 609 INCOBOT UL INUMT OXINA (NT -201) I NJ E C T I ONS A R E SAFE AND EFFECTIVE IN ADUL T SUBJECTS WITH BLEPHAROSPASM ACROSS DOSING INTE R VAL S IN A REPEATED DOSE ST UDY Matthew Brodsky,
More informationScottish Medicines Consortium
Scottish Medicines Consortium clostridium botulinum neurotoxin type A, 100 unit powder for solution for injection (Xeomin ) No. (464/08) Merz Pharma UK Ltd 09 May 2008 The Scottish Medicines Consortium
More informationClinical Policy: IncobotulinumtoxinA (Xeomin) Reference Number: CP.PHAR.231
Clinical Policy: (Xeomin) Reference Number: CP.PHAR.231 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationPrior Authorization Update: Botulinum Toxins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationD. M. Simpson, A. Blitzer, A. Brashear, et al. DOI /01.wnl This information is current as of May 5, 2008
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
More informationClinical Policy: IncobotulinumtoxinA (Xeomin) Reference Number: ERX.SPA.194 Effective Date:
Clinical Policy: (Xeomin) Reference Number: ERX.SPA.194 Effective Date: 01.11.17 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationDYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex)
DYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex) CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Dysport. It does not contain all
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Xeomin) Reference Number: CP.PHAR.231 Effective Date: 07.01.16 Last Review Date 05.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationComparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies
612 Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA P A Hanna J Jankovic Neurosciences Group, Department of Clinical Neurology,
More information& MIGRAINE DIARY YOUR HEADACHE. Talk with your doctor about BOTOX and Chronic Migraine
YOUR HEADACHE & MIGRAINE DIARY Do you really know how many headaches and migraines you have in a month? Keeping a diary like this one can help you find out. If you have 15 or more headache days a month,
More informationMedication Prior Authorization Form
(OnabotulinumtoxinA) Dysport (abobotulinumtoxina) Myobloc (rimabotulinumtoxinb) Xeomin (incobotulinumtoxina) Policy Number: 1042 Policy History Approve Date: 12/11/2015 Revise Dates: 07/07/2017 Next Review:
More informationHeadache and Migraine Treatment
Many of us think of Botox primarily as a cosmetic treatment for lines and wrinkles on the face, but the botulinum toxin that Botox is derived from has a long history of medically therapeutic uses. In fact,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: botulinum_toxin_injection 8/1985 10/2015 10/2016 10/2015 Description of Procedure or Service Description
More informationDYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex)
DYSPORT (Clostridium botulinum type A toxin-haemagglutinin complex) CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Dysport. It does not contain all
More informationWe have been hearing about the Botulinum. Role of Botulinum toxin injection in neurological problems: A Short Review
Review Article Isha Dhungana, MD, PhD Neurology Unit Neuro Center and Polyclinic Prabin Shrestha, MD, PhD Department of Neurosurgery Norvic International Hospital Address for correspondence: Isha Dhungana,
More informationWARNING: DISTANT SPREAD OF TOXIN EFFECT
Dear Doctor, We have enclosed a sample XEOMIN (incobotulinumtoxina) treatment patient consent form for your information. Please be aware that this form is merely intended for use as an example. Merz Aesthetics,
More informationBOTULINUM TOXINS A AND B
DRUG POLICY BOTULINUM TOXINS A B Policy Number: 2014D0017N Effective Date: 9/1/2014 Table of Contents Page COVERAGE RATIONALE... 1 BENEFIT CONSIDERATIONS... 7 BACKGROUND... 8 CLINICAL EVIDENCE... 8 U.S.
More informationAbbreviated Class Review: Botulinum toxins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPharmacy Medical Necessity Guidelines: Botulinum Toxins
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2018 Effective: Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical
More informationOriginal Policy Date
MP 5.01.03 Botulinum Toxin Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index
More informationSee Policy CPT/HCPCS CODE section below for any prior authorization requirements
Effective Date: 4/1/2017 Section: MED Policy No.: 209 Medical Officer 4/1/2018 Date Technology Assessment Committee Approved Date: 4/09;6/10, 01/11; 5/13; 2/15 Medical Policy Committee Approved Date: 11/09;
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Botulinum Toxins (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationBotulinum Toxin Therapy Billing & Coding Update 2016
Botulinum Toxin Therapy Billing & Coding Update 2016 Martin Taylor, DO, PhD Neurology / OrthoNeuro Clinical Associate Professor, Neurology Ohio University College of Osteopathic Medicine Columbus, OH Disclosures
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Botulinum Toxins Reference Number: TCHP.PHAR.1812 Effective Date: 07.01.2018 Last Review Date: 04.13.2018 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
More informationCONSUMER MEDICINE INFORMATION
CONSUMER MEDICINE INFORMATION BOTOX (botulinum toxin, type A) purified neurotoxin complex The information in this leaflet is ONLY a summary and is not a complete statement about BOTOX injection. Your doctor
More informationBotulinum Toxins (BOTOX, DYSPORT, MYOBLOC and XEOMIN)
Botulinum Toxins (BOTOX, DYSPORT, MYOBLOC and XEOMIN) Policy Number: Original Effective Date: MM.04.004 03/14/2006 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 10/01/2013 Section: Prescription
More informationFor peer review only. BMJ Open. For peer review only -
Decline in neutralising antibody titres in secondary nonresponders despite continuous treatment with a botulinum neurotoxin type A preparation free of complexing proteins Journal: Manuscript ID: bmjopen-0-000
More information(ONABOTULINUMTOXINA) RECEIVES U.S
BOTOX (ONABOTULINUMTOXINA) RECEIVES U.S. FDA APPROVAL FOR THE TREATMENT OF URINARY INCONTINENCE IN ADULTS WITH NEUROLOGICAL CONDITIONS INCLUDING MULTIPLE SCLEROSIS AND SPINAL CORD INJURY Clinical Trials
More informationBOTOX Cosmetic (onabotulinumtoxina) before-and-after photo files
BOTOX Cosmetic (onabotulinumtoxina) before-and-after photo files INSTRUCTIONS FOR USE This zip file contains PDF files with images and Important Safety Information to copy and paste into your practice
More informationDisclaimer. All information shared in this presentation is in the public domain.
THE BOTOX STORY Disclaimer All information shared in this presentation is in the public domain. Hence, no trade secret related to drug formulation, manufacturing process, commercial practice, etc. The
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.
Local Coverage Determination (LCD): Botulinum Toxins (L33274) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information CONTRACTOR NAME
More informationALTERNATIVE TREATMENTS
Botox Consent INSTRUCTIONS This is an informed- consent document which has been prepared to help your plastic surgeon inform you concerning BOTOX (Botulina Toxin Type A, Allergan) injection, its risks,
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Clostridium botulinum neurotoxin type A haemagglutinin complex Pharmaceutical form(s)/strength: powder for solution for injection, 300 unit and 500 unit P-RMS:
More informationBOTOX Cosmetic (onabotulinumtoxina) before-and-after
BOTOX Cosmetic (onabotulinumtoxina) before-and-after Moderate to severe crow s feet lines Before After (Day 7) Actual patient. Results may vary. Photos taken at full smile before and after treatment with
More informationScientific Update Laxman Bahroo, MD
Scientific Update Laxman Bahroo, MD Associate Professor Director; Botulinum Toxin Clinic Director; Neurology Residency Program Medstar Georgetown University Hospital Washington, D.C. Disclosures Advisory
More informationPolicy. covered. (spasmodic. Cervical dystonia. injury, or more of. migraine. agents. - Migraine - Migraine. per month. communication, dystonia
Botulinum Toxin Policy Number: 5.01.05 Origination: 02/1998 Last Review: 02/2014 Next Review: 02/2015 Policy BCBSKC will provide coverage for botulinum toxin A and B injections it is determined to be medically
More informationBotulinum Toxin. When Policy Topic is covered The use of botulinum toxin may be considered medically necessary for the following:
Botulinum Toxin Policy Number: 5.01.05 Last Review: 01/2018 Origination: 02/1998 Next Review: 02/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for botulinum toxin
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dysport) Reference Number: CP.PHAR.230 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationArticles Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis
Freely available online Articles Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis Daniel Martinez-Ramirez 1, Juan C. Giugni 1, Erin Hastings 1,
More informationDRUG USE EVALUATION: UTILIZATION OF BOTULINUM TOXIN
There are currently four botulinum toxin (BoNT) products available in the United States: abobotulinumtoxina (ABO), incobotulinumtoxina (INC), onabotulinumtoxina (ONA), and rimabotulinumtoxinb (RIM). They
More informationMEDICATION GUIDE Myobloc (My-o-block) (rimabotulinumtoxinb) Injection
MEDICATION GUIDE Myobloc (My-o-block) (rimabotulinumtoxinb) Injection Read the Medication Guide that comes with MYOBLOC before you start using it and each time MYOBLOC is given to you. There may be new
More informationSEE IMPORTANT SAFETY INFORMATION ON PAGE 2. See Important Safety Information inside.
See Important Safety Information inside. Visit BotoxCosmetic.com to learn more. By prescription only. 1-800-BOTOX-MD Also from the Allergan family of brands: 2010 Allergan, Inc., Irvine, CA 92612. marks
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Xeomin) Reference Number: CP.PHAR.231 Effective Date: 07.01.16 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationNeurotoxins (Botox, Dysport, Myobloc and Xeomin )
Last Review Date: November 10, 2017 Number: MG.MM.PH.01mC Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationUnderstanding Dystonia
Understanding Dystonia Sand Sharks Anthony Richardsen, Lindsey Rathbun, Evan Harrington, Chris Erzen The Essentials What, Why, How What is Dystonia? Dystonias are movement disorders often characterized
More informationCONSUMER MEDICINE INFORMATION
CONSUMER MEDICINE INFORMATION BOTOX (botulinum toxin, type A) purified neurotoxin complex The information in this leaflet is ONLY a summary and is not a complete statement about BOTOX injection. Your doctor
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Myobloc) Reference Number: CP.PHAR.233 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationAetna Better Health of Virginia
Botox (onabotulinumtoxina) Myobloc (rimabotulinumtoxinb) Dysport (abobotulinumtoxina) Xeomin (incobotulinumtoxina) Indications: (use if necessary): Overactive Bladder BOTOX indicated for the treatment
More informationAndy was treated for frown lines and crow s feet. Results may vary. Please see Important Safety Information, including Boxed Warning, inside.
Andy was treated for frown lines and crow s feet. Results may vary. Please see Important Safety Information, including Boxed Warning, inside. Feel confident that you can still look like yourself With BOTOX
More informationThis guide describes some of the important facts about Neurobloc that you need to be aware of, however, it does not replace the advice given to you
This guide describes some of the important facts about Neurobloc that you need to be aware of, however, it does not replace the advice given to you by a healthcare professional. Further very important
More informationWhy is this botulinum toxin prescribed?
Why is this botulinum toxin prescribed? Botulinum Toxin injections are in a class of medications called neurotoxins. When Botulinum Toxin is injected into a muscle, it blocks the nerve signals that cause
More informationPlease see Approved Uses and Important Safety Information, including Boxed Warning, inside.
Please see Approved Uses and Important Safety Information, including Boxed Warning, inside. IT S YOUR STORY, TELL IT YOUR WAY You ve probably heard of BOTOX Cosmetic, but did you know: It s the first and
More informationCynthia was treated for her frown lines and crow s feet. Results may vary. Please see Important Safety Information, including Boxed Warning, inside.
Cynthia was treated for her frown lines and crow s feet. Results may vary. Please see Important Safety Information, including Boxed Warning, inside. Your lines don t define you Get the subtle results you
More informationProfessor Tim Anderson
Professor Tim Anderson Neurologist University of Otago Christchurch 11:00-11:55 WS #91: Shakes Jerks and Spasms - Recognition and Differential Diagnosis 12:05-13:00 WS #102: Shakes Jerks and Spasms - Recognition
More informationSource: *Dystonia facts medically edited by: Charles Patrick Davis, MD, PhD
Source: http://www.medicinenet.com/script/main/art.asp?articlekey=349 Dystonia facts* *Dystonia facts medically edited by: Charles Patrick Davis, MD, PhD Dystonia is a disorder of muscle control; it can
More informationHubert H. Fernandez, MD
Hubert H. Fernandez, MD Associate Professor Co-Director, Movement Disorders Center Director, Clinical Trials for Movement Disorders Program Director, Neurology Residency and Movement Disorders Fellowship
More informationImportant Safety Information
Important Safety Information What is the most important information you should know about Oysport? Spread of Toxin Effects: In some cases, the effects of Dysport and all botulinum toxin products may affect
More informationThis policy addresses only the type B formulation rimabotulinumtoxinb marketed as Myobloc.
RimabotulinumtoxinB NDC CODE(S) 10454-0710-XX Myobloc 2500 UNIT/0.5ML SOLN (SOLSTICE NEUROSCIENCES) 10454-0711-XX Myobloc 5000 UNIT/ML SOLN (SOLSTICE NEUROSCIENCES) 10454-0712-XX Myobloc 10000 UNIT/2ML
More informationDystonias. How are the dystonias classified? One way of classifying the dystonias is according to the parts of the body they affect:
Dystonias What are the dystonias? The dystonias are movement disorders in which sustained muscle contractions cause twisting and repetitive movements or abnormal postures. The movements, which are involuntary
More informationNeurological disorders. Dystonia Search date September 2013 Ailsa Snaith and Derick Wade ...
Search date September 213 Ailsa Snaith and Derick Wade.................................................. ABSTRACT INTRODUCTION: is usually a lifelong condition with persistent pain and disability. Focal
More informationBotulinum toxin type A in the treatment of patients with cervical dystonia
REVIEW Botulinum toxin type A in the treatment of patients with cervical dystonia Allison Brashear Dept of Neurology, Wake Forest University Baptist, Medical Center, Winston Salem, NC, USA Correspondence:
More informationPlease see Important Safety Information, including Boxed Warning, inside.
Sandra was treated in her frown lines and crow s feet areas. Results may vary. Please see Important Safety Information, including Boxed Warning, inside. Approved Uses BOTOX Cosmetic (onabotulinumtoxina)
More informationTreating Adults with Cervical Dystonia
Treating Adults with Cervical Dystonia Learn more about Dysport Talk to your doctor about Dysport and find out if it is right for you. What is Dysport? Dysport is a prescription medicine that is injected
More informationIs OnabotulinumtoxinA Good for Other Head and Face Pain? Disclosures BoNT/A for non- CM Botulinum neurotoxin (BoNT) in clinical use for headache >20
1 2 3 4 5 6 Is OnabotulinumtoxinA Good for Other Head and Face Pain? Disclosures BoNT/A for non- CM Botulinum neurotoxin (BoNT) in clinical use for headache >20 years Efficacy of BoNT type A (onabotulinumtoxina,
More informationINFORMED CONSENT BOTOX INJECTION
. Purchasers of the Patient Consultation Resource Book are given a limited license to modify documents contained herein and reproduce the modified version for use in the Purchaser's own practice only.
More informationInformed Consent Botulina Toxins Botox, Dysport, Xeomin Neurotoxins
Informed Consent Botulina Toxins - Botox Neurotoxins Informed Consent Botulina Toxins Botox, Dysport, Xeomin Neurotoxins INSTRUCTIONS This is an informed-consent document that has been prepared to help
More informationAlbert C. Clairmont, MD Associate Professor-Clinical Department of PM & R The Ohio State University
Botulinum Toxin for Movement Disorders: Physiology, Pharmacology and Evaluation of Patients Albert C. Clairmont, MD Associate Professor-Clinical Department of PM & R The Ohio State University OBJECTIVES
More informationBotulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia
DOI 10.1186/s40064-016-2967-x RESEARCH Open Access Botulinum toxin type A with or without needle electromyographic guidance in patients with cervical dystonia Chuanjie Wu 1, Fang Xue 2, Wansheng Chang
More informationTable of Contents. Preface... xi. Part I: Introduction to Movement Disorders
Table of Contents Visit www.healthreferenceseries.com to view A Contents Guide to the Health Reference Series, a listing of more than 14,000 topics and the volumes in which they are covered. Preface...
More informationClinical Relevance of Botulinum Toxin Immunogenicity
OPEN ACCESS: CURRENT OPINION Biodrugs 2012; 26 (2): e1-e9 1173-8804/12/0002-0001 ª 2012 Benecke, publisher and licensee Adis Data Information BV. This is an open access article published under the terms
More information